PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...
Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic ...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust ...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 ...
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune ...
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in ...
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) — via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire ...
Phoenix, Nov. 6, 2018 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) ...
NEW YORK (Sept 25, 2018) – via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution ...
AUSTIN, Texas—8/28/18– SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology ...
Accessibility Tools